Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study

Table 3 Correlations between radiological response and prognostic systems for first transarterial chemoembolization

Prognostic system	Score, median [IQR]	Grade	Radiological response, n					Spearman R (P value)	Kappa (P value)
			CR	PR	SD	PD	Total
HAP	2 [1-2]	A	42	55	26	10	133	0.27 (0.028)	0.10 (0.020)
		B	50	157	83	42	332
		C	39	157	109	92	397
		D	18	72	81	74	245
mHAP	1 [1-2]	A	56	101	43	15	215	0.29 (0.028)	0.10 (0.020)
		B	64	198	116	80	458
		C	25	126	120	96	367
		D	4	16	20	27	67
mHAP2	2 [2-3]	A	13	11	7	2	33	0.27 (0.028)	0.07 (0.017)
		B	50	91	53	19	213
		C	50	180	98	58	386
		D	36	159	141	139	475
mHAP3	0.41 [0.05-0.83]	A	68	129	61	18	276	0.27 (0.028)	0.10 (0.020)
		B	48	119	65	46	278
		C	26	122	72	56	276
		D	7	71	101	98	277
6&12	9.7 [7.5-12.9]	A	70	114	51	22	257	0.39 (0.026)	0.14 (0.019)
		B	58	145	56	46	305
		C	18	114	85	54	271
		D	3	68	107	96	274

HAP: Hepatoma Arterial-embolization Prognostic; mHAP: Modified HAP; 6&12: Six-and-twelve criteria; ART: Assessment for re-treatment with transarterial chemoembolization; ABCR: Alpha-fetoprotein, BCLC stage, Child-Pugh and Response.